N/A
N=1
Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging
Traumatic Brain Injury · Multiple Sclerosis · Alzheimer's Disease · Tumor
Bottom Line
View on ClinicalTrials.gov: NCT02767609 ↗Enrolled (actual)
1
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcome: Primary: Regional Cerebral Blood Flow Values of the Brain Measured Using Pseudo-continuous Arterial Spin Labeling (pCASL) MRI. — 35.4 ml/100g/min
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Magnetic Resonance Imaging (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Loma Linda University
- Primary completion
- Mar 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Regional Cerebral Blood Flow Values of the Brain Measured Using Pseudo-continuous Arterial Spin Labeling (pCASL) MRI. |
35.4 | — |
Summary
This study will test a new MRI sequence that measures cerebral blood flow (CBF). Because this technique for measuring CBF is new, there is little information on what the normal values for different regions of the brain should be. Information from the study will be used to establish normative CBF values for the brain, improving the reliable use of this technique for the diagnosis of brain injury or disease.
Eligibility Criteria
Inclusion Criteria
- Any person between the ages of 18-90 years, who is undergoing routine magnetic resonance imaging (MRI) of the head with or without contrast at Loma Linda University Medical Center.
- Must be eligible for MRI (no electronic or metal implants that are not MR compatible).
Exclusion Criteria
- Electronic or metal implant that is not MRI safe, pregnancy or claustrophobia.
Data sourced from ClinicalTrials.gov (NCT02767609). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.